– NETHERLANDS, Amsterdam – Modra Pharmaceuticals today announced the appointment of Dr. Hemanshu Shah, Ph.D. and Dr. Klaus Schollmeier, Ph.D. to its supervisory board, bringing more than 50 years of combined experience in the pharmaceutical and biotechnology industry.
They will both provide guidance critical for the acceleration of growth and business development efforts, as well as the company’s plans for the advancement of a lead clinical candidate, ModraDoc006/r, a boosted oral formulation of docetaxel.
Modra recently presented preliminary data from its Phase IIb trial of ModraDoc006/r, which showed positive safety and tolerability profile in metastatic castrate-resistant prostate cancer.
“Hemanshu and Klaus are fantastic additions to Modra’s Supervisory Board as we move into late-stage clinical development with ModraDoc006/r and execute the next stage of our growth as a company. Their experience in medical affairs, corporate development, as well as clinical and commercial development, will be an invaluable asset to us. I am delighted to welcome both of them, and look forward to their insights as we continue to advance our lead program towards pivotal studies as a convenient and better tolerated oral taxane therapy for prostate and breast cancer,” said CEO, Colin Freund.
About Dr. Hemanshu Shah
Dr. Shah has over thirty years of experience in both large pharmaceutical and emerging biotechnology companies including BMS, Astellas, Innate, and Johnson & Johnson. His experience encompasses multiple functional areas including drug development, strategic marketing, business development, and commercial operations with a focus on oncology.
He has a Ph.D. in Pharmaceutical Sciences from Rutgers University and an MBA from the University at Buffalo.
About Dr. Klaus Schollmeier
Dr. Schollmeier is an advisor, board member, and chairman of several biotech companies and mentors several start-ups across Europe. He was CEO of SuppreMol before it was sold to Baxalta. Before that, he served as CEO and Chairman of the Board of Santhera. He also served as managing director of the healthcare/biotechnology group at ING-BHF Bank for ING Group Europe.
Mr. Schollmeier holds a Ph.D. in biology from the University of Düsseldorf.
About Modra Pharmaceuticals
Modra Pharmaceuticals aims to transform taxane therapy by developing therapies that are less toxic, more effective, and can be taken at home in tablet form. The Company’s goal is to dramatically improve the therapeutic outcomes and everyday lives of the hundreds of thousands of cancer patients undergoing taxane therapy worldwide. Modra’s lead program is nearing completion of a randomized Phase 2b clinical study in prostate cancer to further demonstrate the value of the approach, having already shown promising results in earlier studies in prostate and breast cancers.
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.